|Videos|March 14, 2017
Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer
Author(s)Kathleen N. Moore M.D.
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
Advertisement
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
5 Years of Prostate Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
2
Getting on My Ovarian Cancer Awareness Soap Box Again Because I Love My Daughter
3
What Your Friend with Cancer REALLY Needs
4
Placebos in Cancer Clinical Trials: What Patients Need to Know
5